Su Yin Lim

List of Publications by Year
in descending order

31 papers	2,795 citations	304743 22 h-index	434195 31 g-index
31 all docs	31 docs citations	31 times ranked	5789 citing authors

#	Article	IF	Citations
1	Proteinâ€based classification of melanoma differentiation subtypes. Pigment Cell and Melanoma Research, 2022, 35, 471-473.	3.3	1
2	Melanoma Cell State-Specific Responses to TNFÎ±. Biomedicines, 2021, 9, 605.	3.2	1
3	Mitogenâ€activated protein kinase dependency in BRAF/RAS wildâ€type melanoma: A rationale for combination inhibitors. Pigment Cell and Melanoma Research, 2020, 33, 345-357.	3.3	2
4	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. Cancers, 2020, 12, 3374.	3.7	27
5	Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression. Biomolecules, 2020, 10, 1447.	4.0	20
6	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 2020, 11, 1897.	12.8	165
7	Proteomics analysis of the matrisome from MC38 experimental mouse liver metastases. American Journal of Physiology - Renal Physiology, 2019, 317, G625-G639.	3.4	7
8	Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemotherapy and Pharmacology, 2019, 83, 693-704.	2.3	21
9	Tumour-Derived Laminin Î±5 (LAMA5) Promotes Colorectal Liver Metastasis Growth, Branching Angiogenesis and Notch Pathway Inhibition. Cancers, 2019, 11, 630.	3.7	52
10	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 2019, 35, 238-255.e6.	16.8	547
11	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. OncoImmunology, 2019, 8, e1537581.	4.6	61
12	Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 207-228.	7.4	102
13	Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. Mammalian Genome, 2018, 29, 866-878.	2.2	10
14	Interferon Signaling Is Frequently Downregulated in Melanoma. Frontiers in Immunology, 2018, 9, 1414.	4.8	28
15	Liquid biomarkers in melanoma: detection and discovery. Molecular Cancer, 2018, 17, 8.	19.2	74
16	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer, 2017, 141, 594-603.	5.1	91
17	Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 2017, 123, 2118-2129.	4.1	121
18	<scp>PD</scp> â€L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Molecular Medicine, 2017, 9, 167-180.	6.9	172

#	Article	IF	Citations
19	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 2017, 5, 32.	6.8	33
20	Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget, 2016, 7, 28697-28710.	1.8	378
21	Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis. Cancer Microenvironment, 2016, 9, 45-61.	3.1	26
22	Cd11b+ myeloid cells support hepatic metastasis through downâ€regulation of angiopoietinâ€like 7 in cancer cells. Hepatology, 2015, 62, 521-533.	7.3	45
23	IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer. OncoImmunology, 2015, 4, e1027473.	4.6	71
24	IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget, 2014, 5, 11064-11080.	1.8	103
25	Recruitment of myeloid cells to the tumor microenvironment supports liver metastasis. OncoImmunology, 2013, 2, e23187.	4.6	14
26	Recruitment of a myeloid cell subset (CD11b/Gr1^{mid}) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis*. Hepatology, 2013, 57, 829-839.	7.3	183
27	Oxidative Modifications of DAMPs Suppress Inflammation: The Case for S100A8 and S100A9. Antioxidants and Redox Signaling, 2011, 15, 2235-2248.	5.4	72
28	S-Glutathionylation Regulates Inflammatory Activities of S100A9. Journal of Biological Chemistry, 2010, 285, 14377-14388.	3.4	60
29	Pleiotropic Roles of S100A12 in Coronary Atherosclerotic Plaque Formation and Rupture. Journal of Immunology, 2009, 183, 593-603.	0.8	68
30	Oxidative modifications of S100 proteins: functional regulation by redox. Journal of Leukocyte Biology, 2009, 86, 577-587.	3.3	133
31	S-Nitrosylated S100A8: Novel Anti-Inflammatory Properties. Journal of Immunology, 2008, 181, 5627-5636.	0.8	107